PMID- 33409802
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1179-1993 (Electronic)
IS  - 1178-2595 (Linking)
VI  - 35
IP  - 1
DP  - 2021 Jan
TI  - Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and 
      Future Opportunities.
PG  - 11-19
LID - 10.1007/s40290-020-00374-5 [doi]
AB  - The global burden of chronic disorders such as Parkinson's disease (PD) has 
      rapidly increased over recent decades. Despite an increasing understanding of PD 
      pathophysiology, there are no effective therapies capable of stopping or slowing 
      the progression of this neurological condition. It has been suggested that type 2 
      diabetes mellitus (T2DM) may be a risk factor for PD and comorbid T2DM may worsen 
      PD symptoms, as well as accelerate neurodegeneration. In fact, the similar 
      pathological mechanisms shared by PD and T2DM have inspired several studies on 
      the therapeutic potential of T2DM drugs against PD, among which glucagon-like 
      peptide-1 receptor (GLP-1R) agonists are promising candidates. Here, we highlight 
      the mechanisms linking T2DM and PD, as well as the links between insulin 
      resistance (IR) and PD patients' risk of developing cognitive deficits. We also 
      briefly review the effects of GLP-1R agonists on PD and discuss how the 
      successful use of these substances in preclinical models of PD has paved the way 
      for PD clinical trials. We further discuss how recent evidence on the beneficial 
      effects of dulaglutide on cognitive function of T2DM patients may have important 
      implications for PD drug repurposing.
FAU - Victorino, Daniella Balduino
AU  - Victorino DB
AUID- ORCID: 0000-0002-2518-3902
AD  - Discipline of Neuroscience, Department of Neurology and Neurosurgery, Paulista 
      Medical School, Federal University of Sao Paulo, Pedro de Toledo 669, 1st Floor, 
      Sao Paulo, SP, 04039-032, Brazil. dani_balduino@hotmail.com.
FAU - Nejm, Mariana
AU  - Nejm M
AD  - Discipline of Neuroscience, Department of Neurology and Neurosurgery, Paulista 
      Medical School, Federal University of Sao Paulo, Pedro de Toledo 669, 1st Floor, 
      Sao Paulo, SP, 04039-032, Brazil.
FAU - Guimaraes-Marques, Marcia
AU  - Guimaraes-Marques M
AD  - Discipline of Neuroscience, Department of Neurology and Neurosurgery, Paulista 
      Medical School, Federal University of Sao Paulo, Pedro de Toledo 669, 1st Floor, 
      Sao Paulo, SP, 04039-032, Brazil.
FAU - Scorza, Fulvio Alexandre
AU  - Scorza FA
AD  - Discipline of Neuroscience, Department of Neurology and Neurosurgery, Paulista 
      Medical School, Federal University of Sao Paulo, Pedro de Toledo 669, 1st Floor, 
      Sao Paulo, SP, 04039-032, Brazil.
FAU - Scorza, Carla Alessandra
AU  - Scorza CA
AD  - Discipline of Neuroscience, Department of Neurology and Neurosurgery, Paulista 
      Medical School, Federal University of Sao Paulo, Pedro de Toledo 669, 1st Floor, 
      Sao Paulo, SP, 04039-032, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210107
PL  - New Zealand
TA  - Pharmaceut Med
JT  - Pharmaceutical medicine
JID - 101471195
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - Drug Repositioning
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Parkinson Disease/complications/drug therapy/epidemiology
MH  - *Pharmaceutical Preparations
EDAT- 2021/01/08 06:00
MHDA- 2021/10/29 06:00
CRDT- 2021/01/07 06:12
PHST- 2020/12/15 00:00 [accepted]
PHST- 2021/01/08 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2021/01/07 06:12 [entrez]
AID - 10.1007/s40290-020-00374-5 [pii]
AID - 10.1007/s40290-020-00374-5 [doi]
PST - ppublish
SO  - Pharmaceut Med. 2021 Jan;35(1):11-19. doi: 10.1007/s40290-020-00374-5. Epub 2021 
      Jan 7.